Massar

Danish MD, postdoc at #Mayoclinic, Department of #Cardiology. Collecting my jar of a good living life.

[European Society of Cardiology Journals @ESC_Journals]

New in #EJPC: “Effects of empagliflozin in patients at risk of heart failure: the EMPIRE Prevent Metabolic Trial”
🔍 In people with overweight/obesity without diabetes, empagliflozin reduced extracellular volume—a key HF risk mechanism—while epicardial fat remained unchanged.
👉 https://t.co/JQaL1Iz3Cr

@EJPCEiC @SilCastelletti @PTBuketAkinci @PeroneFrancesco @SMosteoru @TimKambic

[Massar @MassarOmard]

The Research Strategy Group met to shape the 2026-2030 strategy for @OUHhospital @kliniskinstitut, where I participated on focusing on global collaboration and research excellence. Grateful for a great team and insightful discussions.

[Massar @MassarOmard]

@adnanalkhouli @MayoClinicCV Congrats, well deserved 👏🏼

[Massar @MassarOmard]

The DanGerShock trial - a significant reduction of mortality with the use of the Impella device in cardiogenic shock patients 🫀! @NEJM @Abiomed @RigsHeart @CHassager JacobEMoller @PCRonline

[ACVCPresident @ACVCPresident]

Do we have a new option in the treatment of #CardShock related to #AMI?
Past ACVC President @CHassager together with Prof. Jacob E Moeller just published the long awaited results of the DanGer Shock trial #ACC24
⬇️ mortality #MCS vs standard care alone

https://t.co/2FbXnXuvAn

[Henry Han @HanCardiomd]

This Mayo Clinic study on 476 #HFpEF patients reveals crucial insights:

Only 26% had no atrial #myopathy, while 31% had isolated LA myopathy, 39% biatrial, and 4% isolated right atrial (RA).

Biatrial myopathy linked to worse outcomes: more #AFib , left and right ventricular dysfunction, severe pulmonary disease, and a staggering 84% higher risk of HF 🏥 or death compared to isolated LA myopathy

https://t.co/6UMSyJgg08

@ESC_Journals @EJHFEiC

[Henry Han @HanCardiomd]

The effect of #SGLT2i on left cardiac remodelling in #HFrEF: Systematic review and meta-analysis

https://t.co/mUUwK31Oxx
@ESC_Journals

[Massar @MassarOmard]

@DmitryAbramovMD Dear Dmitry
First we got hemodynamic data of SGLT2i on HFrEF from the Empire HF trial (see the figure below) and now, we have it on HFpEF with the the CAMEO-DAPA trial as well.

[Edina Hadžiselimović, MD, PhD 💜👩🏻‍⚕️🩺🎶🇩🇰 @DrEdinaH]

& discussion w/ Drs. Emil Wolsk (@HGHHjerte), Henrik Wiggers (@AUHCardio) & RN Camilla Thomassen (OUH). Multifactorial disease surveillance by #MDT?
#GP, #HF_clinic, #dyspnoea_clinic?

@SLKristensen @FinnGustafsson
#DCS_HF2023 @Pallisgaard_MD @kr_johanna

[Research Unit of Cardiology, OUH @CardResearchOuh]

Ready, steady, go 💪🏻
#ESCCongress 2023

@MassarOmard @jhempelheart

[Daniel J Drucker @DanielJDrucker]

While waiting for #heartfailure data from SELECT a glimpse of potential benefit in PPL with #obesity with HFpEF from STEP HFpEF with 2.4mg semaglutide #heartdisease https://t.co/gGOujdJQHm

[Massar @MassarOmard]

#SGLT2i's benefit in #HFpEF, but why and how?
First in HFpEF! SGLT2i's effect on #PCWP by #RHC in a mechanistic randomized trial. #Dapa⬇️PCWP, improving the fundamental hemodynamic abnormality underlying HFpEF. @CircAHA @MayoClinic @yreddyhf #Borlaugslab https://t.co/jIigjBXRAg

[Yogesh Reddy @yreddyhf]

What would you do? Low output heart failure (what CCU literature would call cardiogenic shock) with severe pulm HTN and severe MR on echo, EF 20%, max tolerated GDMT, low CO 2.4 L/min (CI 1.6). Despite severe MR mean PCWP only 24, but mean PA 57, PVR 14.

[Massar @MassarOmard]

Promising preliminary findings in this experimental study!
Results from the STEP #HFpEF: once-weekly #semaglutide in people with HFpEF and #obesity, will be presented at the #ESC conference 25. August!

[Filip K. Knop @Filip_Knop]

"The Cardioprotective Effects of Semaglutide Exceed Those of Dietary Weight Loss in Mice With HFpEF"
https://t.co/nMgHq7N0Ih
Working up appetite for the results of the STEP-HFpEF trials! https://t.co/4VgdCJzMfw
https://t.co/XsfycahLG8

[Massar @MassarOmard]

2/2
Arterial hypoxemia was found to be related to greater elevation in pulmonary vascular pressures at rest and with exercise, and was associated with increased risk of death in HFpEF.

https://t.co/k1dTj2CGki

[Massar @MassarOmard]

Exploring the phenotypes of #HFpEF may help better identify HFpEF risk profile and may be more amenable specific treatment? We found that 10–25% with HFpEF without #lung disease develop arterial #hypoxemia during #exercise.
@MayoClinic @CardResearchOuh @yreddyhf Borlaug
1/2

[Søren Lund Kristensen @SLKristensen]

Next yrs Danish HF meeting will be in Aarhus -and my tenure as organizer has come to an end after 6 yrs, Thx to co-organizers @mortschou, @FinnGustafsson, Lars Køber, Lærke Nelson, @JawadHButt, @ARuwald, @DrEdinaH, @JulieVishram, @MassarOmard, @cardio_dk and pharma for support!

[Julie Hempel @jhempelheart]

Our 💙❤️ beat for the Empire Prevent Trial in both Odense @CardResearchOuh and Copenhagen @HGHHjerte.

So proud to be working with the team: @FuchsAndersen, @mortschou and Jacob Eifer Møller🫀🫀

[Massar @MassarOmard]

Well deserved award 🍾🍾

[Research Unit of Cardiology, OUH @CardResearchOuh]

Huge congrats to Prof. Jacob Eifer Møller with the @novonordiskfond Clinical Distinguished Investigator 2023 - and the DKK 10 mio that follows! 🎉

Jacob receives the award for his research with mechanical circulatory support in cardiogenic shock.

@OUHhospital
@RigsHeart

[Massar @MassarOmard]

Teaming up again with #Borlaugslab. This paper highlights the hemodynamic differences in #HFpEF with #LVEF > 65%. We should rethink some aspects in future HFpEF trials.
@AlessioAlogna @yreddyhf @BurkhoffMd @MayoClinicCV @CardResearchOuh @HFA_President

[HFAPresident @HFA_President]

I would say this paper is probably a game changer due to the explanation of the absence of neurohormonal antagonists and by raising new hypothesis for future HFPEF trials. @GianluSava @mewton_nathan @ARakisheva @m_piepoli @cardioceptor @BiykemB @WilfriedMullens @MarcoMetra

[Massar @MassarOmard]

@MJHundertmark @CircAHA @RDMOxford @UniofOxford Great work, you definitely added some more pieces to the puzzle of SGL2i’s mechanism of action in HF. 👍🏼👏🏼